Clinical trials
Metabolic Dysfunction-associated Fatty Liver Disease clinical trials
Below are recruiting metabolic dysfunction-associated fatty liver disease clinical trials, each written for real people, not researchers. We’re tracking 46 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07070362Recruiting
Digital early warning system for lung injury after liver surgery
This trial tests a digital early warning system to detect acute lung injury after liver surgery. It may help doctors catch breathing problems early so they can treat them faster.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06873165Recruiting
Gut bacteria treatment for fatty liver disease
This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.
TaipeiAges 18–70 - NCT07534241Recruiting
Reishi Mushroom for Fatty Liver Disease
This study tests whether reishi mushroom (a type of fungus) can improve liver health in people with metabolic dysfunction-associated fatty liver disease—a condition where fat builds up in the liver. Researchers want to see if this natural supplement can reduce liver inflammation and improve blood sugar and cholesterol levels.
LahoreAges 35–65 - NCT06739330Recruiting
Thyroid function and fatty liver disease study
This study looks at how your thyroid might be linked to fatty liver disease (MAFLD). It aims to help researchers understand if thyroid problems play a role in this condition, which could lead to better treatments.
Tanta, El-GharbiaAges 18 years+ - NCT07381257RecruitingEarly Phase 1
Rifaximin for fatty liver disease
This trial tests if rifaximin, a gut medication, can help reduce liver fat in people with metabolic fatty liver disease. It may be an option if you have at least one metabolic risk factor and a certain amount of liver fat.
ShanghaiAges 18–75 - NCT07145151RecruitingPhase 2
Studying UBT251 for MASH liver disease
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
Beijing, Beijing MunicipalityAges 18–75 - NCT07463287Recruiting
Fatty liver and colorectal polyp risk study
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07330830Recruiting
Genetics and fatty liver disease in Caribbean and Indian Ocean populations
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
CayenneAges 18 years+ - NCT07592013Enrolling by invitation
Ancestry Supplements for Fatty Liver Disease
This study tests whether a special supplement (made from cacao, nopal, and crickets) can help improve fatty liver disease in people with excess body fat. Fatty liver disease happens when fat builds up in the liver, and this trial investigates whether these natural ingredients can reduce that buildup.
Guadalajara, GuadalajaraAges 18–60 - NCT06953830Enrolling by invitation
Measuring spleen stiffness in veterans with fatty liver disease
This study tests a new way to measure spleen stiffness in veterans with metabolic-dysfunction fatty liver disease. It may help doctors better understand and monitor this condition without invasive procedures.
Columbia, South CarolinaAges 18 years+ - NCT06937749RecruitingPhase 2
Study of IBI362 for liver scarring from MASH
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05945537RecruitingPhase 1
Testing INI-822 in healthy people and those with MASH
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
Camperdown, New South WalesAges 18–70 - NCT07013916Recruiting
Fructose and liver health in fatty liver disease
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
LondonAges 45–65 - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT07737340Recruiting
Metabolic liver disease in new HIV patients
This study looks at liver health in people newly diagnosed with HIV, before they start HIV treatment. It aims to understand early changes in the liver related to metabolism.
Ankara, AnkaraAges 18 years+ - NCT04873258Recruiting
Test a non-invasive tool to screen for fat-related liver disease
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
London, LondonAges 18–80 - NCT05870969Recruiting
Digital monitoring to catch liver cancer risk early
This study tests a digital (computer/phone-based) system to help track people with higher risk of liver cancer so cancers can be found earlier. It may help by guiding regular check-ins and making early diagnosis more efficient.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05974904Recruiting
Study links a liver-related cell marker to fatty liver damage
This study looks at existing health survey data to see whether a specific immune-cell marker (called HsCAR) is related to fatty liver disease and liver scarring. It may help researchers better understand which people are at higher risk for worsening liver damage.
Chongqing, Chongqing MunicipalityAges 18–90 - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT06386094Recruiting
Fatty Liver Disease and Heart Function Study
This study checks how fatty liver disease (a condition where fat builds up in the liver) affects the heart. If you have this liver condition and are between 18 and 65, you may help doctors understand the link between liver health and heart function.
Chandigarh, ChandigarhAges 18–65 - NCT07692438Recruiting
Can Taiwan green propolis help with fatty liver and body fat?
This trial tests whether a natural supplement called Taiwan green propolis can improve blood fats and reduce body fat in people with fatty liver disease (MASLD). If you have fatty liver plus at least one related health issue like high cholesterol, diabetes, or high blood pressure, you may be eligible.
DalinAges 18–80 - NCT06541132Recruiting
Liver fat and heart artery narrowing study
This study looks at whether the amount of fat in your liver, seen on an ultrasound, is linked to the severity of narrowing in your heart arteries. If you had a heart catheterization (angiography) and an abdominal ultrasound, your data may help researchers understand this connection.
Chongqing, Chongqing MunicipalityAges 18–90 - NCT06588699RecruitingPhase 2
Digoxin for NASH liver disease study
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
New Haven, ConnecticutAges 18–75 - NCT06836609RecruitingPhase 1/Phase 2
Study of a new drug for fatty liver disease (MASLD/MASH)
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
Chandler, ArizonaAges 18–65
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metabolic dysfunction-associated fatty liver disease?
- Yes. Clin2 currently lists 46 recruiting metabolic dysfunction-associated fatty liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metabolic dysfunction-associated fatty liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metabolic dysfunction-associated fatty liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Associated Fatty Liver Disease
- Metabolic Dysfunction-Associated Liver Disease
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Metabolic Associated Steatotic Liver Disease
- Non-Alcoholic Fatty Liver Disease
- Fatty Liver
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.